Orchestra BioMed (NASDAQ:OBIO), Inc. is a publicly traded development-stage medical technology company that focuses on the commercialization of cardiovascular and electrophysiology products alongside a growing biotherapeutics pipeline. With its common shares listed on the NASDAQ Stock Market under the symbol OBIO, the company leverages a combination of internally developed technologies and strategic licensing agreements to deliver solutions aimed at reducing procedural complications and improving patient outcomes in interventional cardiology and cardiac electrophysiology.
The company’s cardiovascular intervention portfolio is anchored by the MGuard® family of devices, which incorporates a proprietary MicroNet® mesh layer designed to capture embolic debris during balloon angioplasty and stent deployment. These devices are approved for use in multiple international markets and are supported by clinical data demonstrating reductions in peri-procedural myocardial infarction and no-reflow phenomena. In parallel, Orchestra BioMed is advancing ProtectIR™, an esophageal cooling system for use during atrial fibrillation ablation procedures, with the aim of reducing thermal injury to the esophagus—a key safety concern in complex electrophysiology treatments.
Founded through a series of mergers and asset acquisitions in the mid-1990s, Orchestra BioMed has steadily expanded its offerings across geographies, establishing distribution and regulatory pathways in Europe, Asia, Latin America and parts of the Middle East. The company operates research and development facilities in the United States and Israel, leveraging cross-disciplinary expertise in materials science, engineering and translational medicine. This global footprint enables Orchestra BioMed to conduct multi-center clinical studies and to support regulatory submissions in major markets worldwide.
Leadership at Orchestra BioMed comprises executives with extensive experience in medical device commercialization, strategic licensing and life-science investment. Headquartered in Cleveland, Ohio, the management team is supported by a board of directors and scientific advisory groups that guide the company’s clinical development strategies and market expansion plans. Building on its heritage of innovation, Orchestra BioMed continues to pursue new indications for its existing platforms while evaluating complementary biotherapeutic candidates to address unmet needs in cardiovascular and inflammatory disease.
